Project Management Medical

Wei Xia, Ph.D.

Metuchen, NJ

Mobile: 917-***-****

Email: ******@*****.***

SUMMARY OF QUALIFICATIONS

* **** ******** ********* ******* expertise in sequencing and sequence analysis for

mutation analysis (genomic DNA from cells, blood, FFPE) and primer walking, PCR and

RT PCR, cloning, mutagenesis, gene synthesis, project management and customer

GLP experience as a study director to manage and work on sequencing verification projects

for virus banks and cell banks

Hands on next generation sequencing experiences including optimization of library

preparation for next generation sequencing, magnetic beads selection for the PCR

purification step of library preparation and development of a next generation sequencing

panel for genetic diseases

12 year training and research in cancer biology and cancer genetics; studied two novel

candidate tumor suppressor genes in prostate cancer and breast cancer respectively for

their genetic alterations and roles in tumorigenesis

WORK EXPERIENCES

Senior Scientist, GENEWIZ, South Plainfield, New Jersey, 2010 08/2013

Scientist II, GENEWIZ, South Plainfield, New Jersey, 03/2008 /2010

My responsibilities and experiences during this period of time include

Leading sequencing and molecular biology services including PCR and sequencing for

•

mutation analysis for human samples, plasmid primer walking and sequence

confirmation, cloning, mutagenesis, gene synthesis; analyzing sequencing results and

writing reports

Leading GLP projects as a study director for virus or cell line verification by PCR or

•

RT PCR and sequencing; writing study protocols, study reports and SOPs

Leading a troubleshooting team to handle difficult projects from VIP clients (core

•

facilities at Millennium, Merck, Novartis, etc.) and communicating with the clients

Leading R&D projects

•

Page of 3

Optimization of library preparation for archived ovarian cancer FFPE samples for

next generation sequencing with Ion Torrent PGM

Development of a NGS based inherited disease panel for newborn screening

Magnetic beads selection for the PCR purification step of library preparation

Sequencing method validations for QA purpose

Training and providing technical guidance to molecular biology production teams at

•

satellite sites

Supervising 1 Ph.D. scientist and 2 associate scientists

•

Associate Research Scientist, the Institute for Cancer Genetics, Columbia University

Medical Center, New York, 10/2004 2/2008

Postdoctoral Research Scientist, the Institute for Cancer Genetics, Columbia University

medical center, New York, 10/2001 10/2004

Research in cancer biology and cancer genetics from 10/2001 to 2/2008

•

Studied genetic variation, signaling pathways and function of a novel candidate tumor

•

suppressor gene, BAF180 in breast cancer

6 year research experience including genetic analysis for breast tumor cell lines and

•

primary breast tumor samples, generation of expression and knockout constructs, re

expression in null cell lines and siRNA knockdown in normal cells via transient

transfection, cell cycle analysis by FACS and gene expression regulation by real time

PCR, western blot, ChIP assay and luciferase reporter assay

EDUCATION

Ph.D. in Biomedical Sciences., Department of Microbiology, Mount Sinai School of

Medicine, New York University, New York, USA

Trained in cancer biology and cell signaling (signal transduction)

•

Studied a novel gene identified in the lab for its signaling pathways and tumor

•

suppression function in prostate cancer

6 year bench experience including mammalian cell culture, transfection and

•

infection, cell line generation, western blot, immune fluorescent staining and

molecular biology

Bachelor of Science, Department of Microbiology, Shandong University, Jinan, China.

PUBLICATIONS

Page of 3

Wei Xia, Satoru Nagase, Amy Montia, Megan Keniry, Tao Su, Hanina Hibshoosh and

Ramon Parsons. The gene encoding chromatin remodeling factor BAF180 is a candidate

tumor suppressor in sporadic breast cancer (Cancer Research, Vol. 68, 1667 1674, March

15, 2008).

Wei Xia and Irwin Gelman. Mitogen induced, FAK dependent tyrosine phosphorylation of

the SSeCKS scaffolding protein. (Exp Cell Res. 2002 Jul 15; 277(2): 139 51).

Wei Xia, Pam Unger, Lorraine Miller, Joel Nelson and Irwin Gelman. The Src Suppressed C

Kinase Substrate, SSeCKS, is a Potential Metastasis Inhibitor in Prostate Cancer (Cancer

Research, Vol. 61, 5644 5651, July 15, 2001).

Page of 3

Contact this candidate